Latest Mass Tort News and Updates

How much is too much? Sometimes, too much business is a very good problem to have. What about information and data that is so vast that it becomes cumbersome for your business to function properly, and it feels like an anchor is pulling your…

Diabetes is a widespread problem throughout the country. In fact, it's so prevalent that it's now commonplace. This is why various pharmaceuticals are quick to find a cure drug or, at the very least, a "band-aid" solution to this ever-growing…

Following up on our last month's newsletter about drugs causing more harm than good, there apparently is another drug that fits that mold namely Fluoroquinolones. A variety of illnesses such as urinary tract infections and respiratory are treated…

Our drafted PI Demand Letter begins at the point of impact and ends with the medical chronology of treatment. It guides the adjuster through all that the claimant has lost as a result of the insured's negligence.

In PI matters, we are…

Whenever a drug comes on the market to enhance the lives of its consumers, the drug, more probable than not, does anything but. One such example is Lipitor. Known by its technical moniker Atorvastatin, was marketed and used to lower cholesterol.…

Bringing an action such as the one involving Xarelto requires a myriad of paperwork to be prepared and served unto the defendants. Neural IT has a great track record of producing quality work in both the Mass Tort & Personal Injury arenas.…

The drug Zofran (Ondansetron) was manufactured to help cancer patients to treat nausea that usually follows chemotherapy treatments. The FDA's approval of Zofran was limited to only this use. However, manufacturer GlaxoSmithKline took the liberty…

The antipsychotic drug Risperdal is causing a whirlwind of lawsuits in courtrooms around the country as victims of this drug, mostly male, are getting what they haven't signed up for. Men and boys who take the antipsychotic drug to treat bipolar…

Boston Scientific Corp. (henceforth "Defendant"), a developer & manufacturer of medical devices, in November 2014, was ordered to pay four women over $26 million after a Miami federal court jury found that it was liable for marketing faulty…

Sanofi has informed the investors that it is planning to bring back Zantac with the generic pharmaceutical ingredient found in Pepcid; famotidine.

Last year, Sanofi had to…